Date published: 2025-12-16

1-800-457-3801

SCBT Portrait Logo
Seach Input

RBKS Inhibitors

RBKS (Ribokinase) inhibitors belong to a class of chemical compounds that primarily target the enzyme ribokinase, an essential player in cellular metabolism. Ribokinase is responsible for phosphorylating ribose, a critical step in the conversion of ribose into ribose-5-phosphate, an important component of the pentose phosphate pathway (PPP). The PPP is a crucial metabolic pathway that provides the cell with ribose for nucleotide synthesis and generates reducing equivalents in the form of NADPH, used in various biosynthetic reactions and oxidative stress defense. By inhibiting ribokinase, RBKS inhibitors disrupt the normal flow of ribose metabolism, leading to profound impacts on cellular physiology.

The mechanism of action of RBKS inhibitors involves binding to the active site of ribokinase, interfering with its ability to catalyze the phosphorylation of ribose. This disruption prevents ribose from entering the PPP, affecting nucleotide production and NADPH generation. Consequently, cells exposed to RBKS inhibitors may experience reduced DNA and RNA synthesis due to limited ribose-5-phosphate availability, which can have downstream effects on cell growth and proliferation. Additionally, the decrease in NADPH levels can compromise the cell's ability to combat oxidative stress, making it more vulnerable to reactive oxygen species. RBKS inhibitors are valuable tools in scientific research for studying cellular metabolism and understanding the role of ribokinase in maintaining cellular homeostasis. Their ability to perturb nucleotide biosynthesis and redox balance provides insights into the fundamental processes governing cell function and survival, offering potential applications in various areas of biological and biochemical research.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$25.00
$117.00
$209.00
27
(1)

Inhibits BCR-ABL kinase, studied in the research of CML.

Cisplatin

15663-27-1sc-200896
sc-200896A
100 mg
500 mg
$76.00
$216.00
101
(4)

Crosslinks DNA, leading to DNA damage and cell death.

Tamoxifen

10540-29-1sc-208414
2.5 g
$256.00
18
(2)

Selective estrogen receptor modulator (SERM) for breast cancer.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

Targets multiple kinases in angiogenesis and cell signaling.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$62.00
$112.00
$214.00
$342.00
74
(2)

Inhibits EGFR kinase in non-small cell lung cancer.

Methotrexate

59-05-2sc-3507
sc-3507A
100 mg
500 mg
$92.00
$209.00
33
(5)

Inhibits dihydrofolate reductase, interfering with DNA synthesis.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

Proteasome inhibitor used in multiple myeloma therapy.

Taxol

33069-62-4sc-201439D
sc-201439
sc-201439A
sc-201439E
sc-201439B
sc-201439C
1 mg
5 mg
25 mg
100 mg
250 mg
1 g
$40.00
$73.00
$217.00
$242.00
$724.00
$1196.00
39
(2)

Stabilizes microtubules, disrupting cell division.

MDV3100

915087-33-1sc-364354
sc-364354A
5 mg
50 mg
$240.00
$1030.00
7
(1)

Androgen receptor antagonist for prostate cancer.

Vemurafenib

918504-65-1sc-364643
sc-364643A
10 mg
50 mg
$115.00
$415.00
11
(1)

Targets mutant BRAF kinase in melanoma.